The drug, vincristine, is used to treat leukemias, lymphomas and brain tumors. Physicians say that the shortage of this chemotherapy drug is uniquely problematic because there is no appropriate alternative.
Physicians also are warning that supply has been so hard to find that they may soon be forced to ration doses.
“This is truly a nightmare situation,” said Yoram Unguru, MD, a pediatric oncologist at the Herman and Walter Samuelson Children’s Hospital at Sinai in Baltimore, told The New York Times. “Vincristine is our water. It’s our bread and butter. I can’t think of a disease in childhood cancer that doesn’t use vincristine.”
There used to be two suppliers of vincristine, Pfizer and Teva Pharmaceuticals. However, earlier this year, Teva decided to discontinue production of the drug, making Pfizer the sole supplier.
The FDA told The New York Times that Pfizer has run into manufacturing issues, but it is working to improve the availability of the cancer drug.
Pfizer said it is working to speed up shipments of vincristine in the next few weeks to “support three to four times our typical production output.”
More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.